Study of a blood protein level in autoimmune disease
Part of Immune system & allergy clinical trials.
This study looks at how a specific protein on cell surfaces (called STIM1) appears in people with autoimmune diseases. The goal is to understand what affects this protein and how it may relate to autoimmune illness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with an autoimmune disease
- You have not taken rituximab within the past 12 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood, tissue, and other samples from people with autoimmune diseases like Crohn's disease, multiple sclerosis, or lupus. Researchers will study your immune cells (T cells) to learn what they are attacking, which could lead to better treatments in the future.
This study looks at blood “biomarkers,” or measurable body signals, in people with autoimmune diseases, vasculitis, or autoinflammatory conditions. The goal is to better understand these illnesses and how they relate to disease activity.
This study looks at blood and immune cell markers (autoantibodies and immune cell “signatures”) to better understand autoimmune conditions, including lupus. It may help researchers identify which markers are linked to disease and how immune cells respond after vaccination.
This study measures blood “biomarkers” (signals in blood) to better understand inflammatory diseases, including autoimmune and autoinflammatory conditions. You may be asked to give blood samples now and possibly extra samples if needed for testing.
This study looks at the distribution of a type of immune protein called immunoglobulin in people with autoimmune diseases or lymphoma. It aims to understand how these proteins are altered in these conditions.
This study looks at immune cells in people with certain autoimmune diseases or immune deficiencies. The goal is to understand how these cells work, which may help improve future treatments.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.